ArticleTheranostics2020

Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.

Hongyi Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.